Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alzamend Neuro, Inc.ALZN · Entity 8081 | Director | April 30, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alzamend Neuro, Inc.
Report date April 30, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2035-11-12 | Direct | 60,000 |
Reported balance
After 2026-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-17 · Grant · Acquired 60,000 · Balance 60,000 F1: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Oram to purchase 60,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Oram to purchase 60,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2026 Filed Aug 5, 2026 01:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001214659-26-009588 · marketforms-73667.xml · derivative · entry 1 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-11-12 F1 · derivative.exercise_date: On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Oram to purchase 60,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-004010 · marketforms-55805.xml · derivative · entry 2 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: 2,778 and 47,222 restricted shares previously vested on September 13, 2021 and October 13, 2021, respectively, with the final 50,000 shares of restricted stock vesting on March 15, 2022. Read SEC document |
| March 15, 2022 Filed Mar 16, 2022 20:30 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-004010 · marketforms-55805.xml · nonDerivative · entry 1 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 47,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010560 · marketforms-54023.xml · derivative · entry 2 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 47,222 shares Expires 2022-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: The restricted stock grant was amended on October 13, 2021, such that 47,222 shares of restricted stock vested on October 15, 2021, and the remaining 50,000 shares of restricted stock shall vest on March 15, 2022. 2,778 shares previously vested on September 13, 2021. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 47,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-010560 · marketforms-54023.xml · nonDerivative · entry 1 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionRestricted Stock Grant · Derivative | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-009542 · marketforms-53815.xml · derivative · entry 2 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,222 Underlying: Common Stock · 2,778 shares Expires 2024-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F3 · derivative.exercise_date: The restricted stock grant vests in 36 equal monthly installments commencing on September 13, 2021. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | Exercise / conversionCommon Stock | 2,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-009542 · marketforms-53815.xml · nonDerivative · entry 1 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the vesting of restricted stock. Read SEC document |
| June 15, 2021 Filed Jul 16, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantStock Options (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-21-007596 · marketforms-53422.xml · derivative · entry 2 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-09-12 F3 · derivative.exercise_date: The stock options (the "Options") vest in 36 equal monthly installments commencing on September 13, 2021 and are exercisable upon vesting. Read SEC document |
| June 15, 2021 Filed Jul 16, 2021 21:00 UTC | Alzamend Neuro, Inc. ALZN · Entity 8081 | GrantRestricted Stock Grant · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-007596 · marketforms-53422.xml · derivative · entry 1 Oram Jeffrey · CIK 0001864444 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-09-13 F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Common Stock, par value $0.0001, of Alzamend Neuro, Inc. F2 · derivative.exercise_date: The restricted stock grant vest contemporaneously with the Options (as defined below). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.